The DOI matches its Crossref record.
Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis
Open accessAbstract
Oncotype DX is a commercial assay frequently used for making chemotherapy decisions in estrogen receptor (ER)-positive breast cancers. The result is reported as a recurrence score ranging from 0 to 100, divided into low-risk (<18), intermediate-risk (18-30), and high-risk (≥31) categories. Our pilot study showed that recurrence score can be predicted by an equation incorporating standard morphoimmunohistologic variables (referred to as original Magee equation). Using a data set of 817 cases, we formulated three additional equations (referred to as new Magee equations 1, 2, and 3) to predict the recurrence score category for an independent set of 255 cases. The concordance between the risk category of Oncotype DX and our equations was 54.3%, 55.8%, 59.4%, and 54.4% for original Magee equation, new Magee equations 1, 2, and 3, respectively. When the intermediate category was eliminated, the concordance increased to 96.9%, 100%, 98.6%, and 98.7% for original Magee equation, new Magee equations 1, 2, and 3, respectively. Even when the estimated recurrence score fell in the intermediate category with any of the equations, the actual recurrence score was either intermediate or low in more than 80% of the cases. Any of the four equations can be used to estimate the recurrence score depending on available data. If the estimated recurrence score is clearly high or low, the oncologists should not expect a dramatically different result from Oncotype DX, and the Oncotype DX test may not be needed. Conversely, an Oncotype DX result that is dramatically different from what is expected based on standard morphoimmunohistologic variables should be thoroughly investigated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline update
Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L., Hayes, D. F., Lakhani, S. R., Chavez-MacGregor, M., Perlmutter, J., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02309 · Cited by 1,574
Prognostic and predictive biomarkers in breast cancer: Past, present and future
Nicolini, A., Ferrari, P., & Duffy, M. J. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.010 · Cited by 424
Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L., Hayes, D. F., Lakhani, S. R., Chavez-MacGregor, M., Perlmutter, J., et al. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0904-sa · Cited by 374
Multigene prognostic tests in breast cancer: past, present, future
Győrffy, B., Hatzis, C., Sanft, T., Hofstatter, E., Aktas, B., & Pusztai, L. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0514-2 · Cited by 257
Gloyeske, N. C., Dabbs, D. J., & Bhargava, R. (2014) · American Journal of Clinical Pathology · doi:10.1309/ajcp34cysatwfdpq · Cited by 63
Self-citation
Metadata
- Authors
- Klein, M. E., Dabbs, D. J., Shuai, Y., Brufsky, A. M., Jankowitz, R., Puhalla, S. L., & Bhargava, R.
- Venue
- Modern Pathology
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 26
- Issue
- 5
- Pages
- 658-664
- ISSN
- 0893-3952 (ISSN-L)
- OpenAlex
- W2022767256
- Cited by
- 196
- References
- 0
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. https://app.cochat.ai/papers/10.1038/modpathol.2013.36
- The paper
- Klein, M. E., Dabbs, D. J., Shuai, Y., Brufsky, A. M., Jankowitz, R., Puhalla, S. L., & Bhargava, R. (2013). Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. Modern Pathology. https://doi.org/10.1038/modpathol.2013.36
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.